Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neuroblastoma 1Lymphoma, Large B-Cell, Diffuse 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 54enzalutamide 47apalutamide 37Specimen Handling 37Androgen Antagonists 34Abiraterone Acetate 32Prednisone 29darolutamide 28Radiosurgery 27Pluvicto 23Docetaxel 23abiraterone 22Radiotherapy 21Leuprolide 19Biopsy 16relugolix 14acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 14Surveys and Questionnaires 13gallium 68 PSMA-11 12Triptorelin Pamoate 12Gonadotropin-Releasing Hormone 12Radiation 11Nivolumab 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11cabazitaxel 10bicalutamide 10X-Rays 10Standard of Care 10Goserelin 9Carboplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Antibodies × 90 days × Clear all
NCT06451497 2026-04-02

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

Phase 1 Recruiting
100 enrolled
BreastGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡